{
  "docId": "019de074-640b-7614-ba57-564b2e029ae4",
  "docSlug": "dcb04f24edfbf49f2d2db8f66e75d66c",
  "documentTitle": "Sarissa Capital | Activist Presentation Deck | 109 slides",
  "authorId": "sarissa-capital",
  "authorName": "Sarissa Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 109,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Uses visual callouts (red boxes, arrows, question marks) to emphasize the contradiction between company claims and regulatory reality.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-640b-7614-ba57-564b2e029ae4/35",
  "deckHref": "/decks/019de074-640b-7614-ba57-564b2e029ae4",
  "deckJsonHref": "/decks/019de074-640b-7614-ba57-564b2e029ae4.json",
  "deckAnchorHref": "/decks/019de074-640b-7614-ba57-564b2e029ae4#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.32,
        "x": 0.63,
        "y": 0.38
      },
      "kind": "callout",
      "text": "As FDA responsibilities include Puerto Rico and FDA extended Vascepa’s label in 2019 incremental “regulatory approval” in Puerto Rico is a disingenuous attempt by company to pad its 2022 progress",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13c5fec7-b642-48d8-bf77-cc5485a526c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.15,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Amarin January 10, 2023 Press Release: Secured six International regulatory approvals, including Hong Kong, Bahrain, Puerto Rico, Saudi Arabia, Australia and Switzerland.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a95fb5bd-a742-454f-80e4-74cbdc6df16d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.15,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "FDA's responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, and other U.S. territories and possessions.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aabef1ca-caa1-4dfa-b1d8-e4c618fff9ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Sources: AMRN First Quarter 2022 and January 10, 2023 Press Release; FDA Website",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eea8a172-4bcf-48d1-9dc9-93caba10a51b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "And in touting 2022 progress, management is really stretching the definition of “international” approvals",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3c426d0-633b-4ed0-ac68-f7beb7cf972b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "63bd24ea-4cfe-40ac-a675-24eebe8540d2",
      "evidence": "Exposing disingenuous claims by comparing company statements against regulatory facts.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 63,
      "from": 14,
      "beatId": "98f8728e-8e6f-4524-abbe-b936d0ae5c62",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The deck agitates the problem by highlighting Amarin's poor management decisions and lack of alignment with shareholder interests",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}